Accelerating diverse, evidence-based cancer interventions via pragmatic trials for improved health equity with UG3/UH3 funding support.
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: June 14, 2025 (New) | July 14, 2025 (Renewal/Resubmission/Revision) | October 17, 2025 (New) | November 17, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $500,000 direct costs/year (UG3, max 2 years); up to $750,000 direct costs/year (UH3, max 4 years); total project period up to 6 years.
Summary: Supports pragmatic trials to test evidence-based cancer-related interventions across the cancer control continuum, emphasizing health equity and diverse U.S. populations/settings.
Key Information: UG3/UH3 phased cooperative agreement; clinical trial required; milestones must be met for UH3 transition; non-domestic organizations not eligible.
This opportunity from the National Cancer Institute (NCI) aims to accelerate the development and testing of evidence-based cancer-related interventions that address the diversity of people, places, and contexts across the United States. The program specifically supports pragmatic trials—studies designed to evaluate interventions in real-world settings—to improve cancer-related outcomes across the cancer control continuum (prevention, detection, diagnosis, treatment, survivorship, and end-of-life care).
The funding mechanism is a two-phase UG3/UH3 cooperative agreement:
Interventions may include behavioral, technology-mediated, community-based, healthcare delivery, multilevel, or implementation strategies. Projects are encouraged to focus on populations experiencing health disparities and settings with limited resources.